Outlook in 2013

Multi-protein inflammasomes are being implicated in a surprising number of diseases, and researchers are keen to find out why.

Combining imaging techniques can provide a wealth of information about disease.

Real-time imaging of a patient's body is guiding surgeons and radiologists past healthy tissue to the diseased cells.

Imaging the brains of Alzheimer's patients provides insights into the way this insidious disease progresses.

Many medical images are used once then filed away. This trove of clinical data should be made available to biomedical researchers, says Alan Moody.

From image-analysis software to lens-free microscopes that fit on a mobile phone, new tools are providing pathologists with clearer and more informative images.

The winner of the 2007 Nobel Prize in Chemistry Gerhard Ertl ponders biology's big questions with Diane Wu.

Dan Shechtman, the winner of the 2011 Nobel Prize in Chemistry, speaks to Valerie Gerard about creating leaders and achieving prosperity though technological entrepreneurship.

Rebecca Melen talks to Robert Grubbs, the joint winner of the 2005 Nobel Prize in Chemistry, about how his research is being applied to many different processes.

Are biofuels the way forward, or should we be looking to advanced solar technologies to power the future? The debate began on Lindau and continues here.

Richard R. Ernst pioneered one- and two-dimensional nuclear magnetic resonance (NMR), and talks to Stephanie Harris about why dimensions are important in life as well as in science.

Knowing the structures of G-protein-coupled receptors, says Lindau keynote speaker Brian Kobilka, should help with drug development. But how is this progressing?

Richard Schrock, a recipient of the 2005 chemistry prize, speaks with Jonathan Moerdyk about whether olefin metathesis, the field he helped to pioneer, has peaked.

Tuberculosis is one of the world's most lethal infectious diseases. Further progress in consigning it to the past is a massive challenge. By Tom Paulson.

There are several new tests for tuberculosis in the pipeline, but they must be shown to be effective in areas with limited resources and a heavy burden of HIV.

Universities should forego profits from tuberculosis, say David G. Russell and Carl F. Nathan.

Researchers are on the hunt for a better alternative to the BCG vaccine.

A narrow definition of risk is hampering the search for new methods of tuberculosis control, say Christopher Dye and Mario Raviglione.